Systemic lupus erythematosus (sle) Trials in New York, United States
Conditions / Systemic lupus erythematosus (sle) / New York, United States
Systemic lupus erythematosus (sle) has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01753401 | Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease | COMPLETED | PHASE4 |
| NCT04726553 | Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE | UNKNOWN | EARLY_PHASE1 |
| NCT04058028 | Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 |
| NCT03626311 | Omega-3 Replacement With Krill Oil in Disease Management of SLE | COMPLETED | NA |
| NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | RECRUITING | — |
| NCT05934149 | Lupus Landmark Study: A Prospective Registry and Biorepository | RECRUITING | — |
| NCT03978520 | A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 |
| NCT05934149 | Lupus Landmark Study: A Prospective Registry and Biorepository | RECRUITING | — |
| NCT04451772 | A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State | COMPLETED | PHASE2 |
| NCT05000216 | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | TERMINATED | PHASE2 |